View Document Preview and Link Document Date: 2015-03-16 01:05:14 Open Document File Size: 143,64 KB Share Result on Facebook
City Campochiaro / / Company ESC / Regeneron Pharmaceuticals Inc. / Restriction Working Group / AMD / GE / Bayer Australia Ltd. / PBAC / / Country Australia / / Currency USD / / Event FDA Phase / Product Issues / Business Partnership / Judicial Event / / Facility Consumer Comments facility / BCVA AFB / stable VA / / IndustryTerm authority applications / telephone application / / MedicalCondition Hypertension GAL / macular edema / hypertension / central retinal vein occlusion / disease / macular degeneration / diabetic retinopathy study / unilateral blindness HR / retinal vein occlusion / eye disease / AFB RBZ Myocardial infarction GALILEO / Cataract GALILEO / gastrointestinal disorders / / Organization Congress / Pharmaceutical Benefits Advisory Committee / Department of Human Services / Human Services Authority / Complex Drugs Unit / Repeated Intravitreal Administration of VEGF Trap-Eye / Therapeutic Goods Administration / Department of Human Services Prior Written Approval of Complex Drugs Reply Paid / Department of Human Services Any / Medicare / / Person Intravitreal Aflibercept / Component Aflibercept / / / Position Governor / Dental Medical Practitioners Nurse / Chief Executive / Program GENERAL / nurse / economic model / first author / General / / Product GALILEO injection / Sham injection / Aflibercept Sham injection / Estimated injections / DM et al. Intravitreal Aflibercept Injection / Trial Aflibercept Sham injection / Total injections / Intravitreal Aflibercept Injection / Efficacy / comparative data / Intravitreal / / ProvinceOrState Virginia / Pennsylvania / / PublishedMedium Ophthalmology / British Journal of Ophthalmology / / Technology author Protocol / tomography / / URL www.humanservices.gov.au / / SocialTag 
7.1 AFLIBERCEPT 4 mg/0.1 mL injection, 1 x 0.1 mL vial, 4 mg/0.1 mL injection, 1 x 0.09 mL syringe; Eylea®; Bayer Australia Ltd.